

# Antonio Galvano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9271771/publications.pdf>

Version: 2024-02-01

63  
papers

1,691  
citations

257450

24  
h-index

302126

39  
g-index

64  
all docs

64  
docs citations

64  
times ranked

3285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103525.	4.4	32
2	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	4.4	26
3	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	3.2	0
4	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
5	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 10519-10519.	1.6	0
6	Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21525-e21525.	1.6	2
7	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	3.2	7
8	Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	3.2	3
9	Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103282.	4.4	3
10	Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests (SEDRT) (CARG+CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12510-e12510.	1.6	1
11	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021, 2, 173-196.	1.2	14
12	The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8432.	2.6	16
13	Cancer of Exocrine Pancreas. <i>UNIPA Springer Series</i> , 2021, , 645-674.	0.1	0
14	Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., <i>J Bone Oncol</i> )	0.0	0
15	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	37
16	Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 7083-7088.	1.1	4
17	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 474.	3.8	51
18	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12

#	ARTICLE	IF	CITATIONS
19	The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020, 85, 101994.	7.7	89
20	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534.	3.7	15
21	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020, 37, 1145-1155.	2.9	102
22	COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 734.	2.8	38
23	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16093-e16093.	1.6	1
24	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019, 18, 100252.	2.4	23
25	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 68-75.	4.4	4
26	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	3.7	4
27	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	2.9	80
28	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	3.2	27
29	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	2.4	10
30	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	3.2	48
31	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	13
32	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
33	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 471-478.	3.0	5
34	Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. <i>International Journal of Cancer</i> , 2018, 142, 1277-1284.	5.1	81
35	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 13379.	3.3	66
36	Indications for Locoregional Tumor Therapies: CRC Liver Metastases. , 2018, , 83-106.		0

#	ARTICLE	IF	CITATIONS
37	The use of SAME in chemotherapy-induced liver injury. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 70-77.	4.4	21
38	Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. <i>Oncotarget</i> , 2018, 9, 17906-17914.	1.8	5
39	Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOX regimen, in metastatic gastric cancer. <i>Oncotarget</i> , 2018, 9, 20339-20350.	1.8	5
40	Real life triplet FIr/FOX chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. <i>Oncotarget</i> , 2018, 9, 31861-31876.	1.8	4
41	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. <i>Current Cancer Drug Targets</i> , 2018, 18, 697-705.	1.6	34
42	Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study. <i>Oncology</i> , 2017, 92, 94-100.	1.9	7
43	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 227-233.	4.4	15
44	Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy. <i>Oncotarget</i> , 2017, 8, 37875-37883.	1.8	12
45	“Back to a false normality” new intriguing mechanisms of resistance to PARP inhibitors. <i>Oncotarget</i> , 2017, 8, 23891-23904.	1.8	24
46	Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin. <i>Oncotarget</i> , 2017, 8, 71924-71932.	1.8	26
47	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016, 7, 47821-47830.	1.8	36
48	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016, 37, 7109-7118.	1.8	24
49	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 20-32.	4.4	31
50	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 188-197.	3.2	19
51	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 150-157.	4.4	81
52	Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1-5.	3.1	8
53	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	1.8	103
54	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	1.8	134

#	ARTICLE	IF	CITATIONS
55	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, 3565-3565.	1.6	0
56	Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0124587.	2.5	27
57	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Digestive and Liver Disease, 2015, 47, 324-330.	0.9	43
58	Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. Expert Opinion on Investigational Drugs, 2015, 24, 125-132.	4.1	5
59	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opinion on Biological Therapy, 2015, 15, 45-59.	3.1	8
60	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	1.8	77
61	Ramucirumab and its use in gastric cancer treatment. Drugs of Today, 2014, 50, 613.	1.1	3
62	Monoclonal antibodies in gastrointestinal cancers. Expert Opinion on Biological Therapy, 2013, 13, 889-900.	3.1	18
63	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. Oncology, 2013, 85, 306-311.	1.9	15